In fiscal 2025, which ended Sep 30, 2025, Bodhi Tree Biotechnology Inc. used $150,166 of cash from operations.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Sep 30, 2025
|
|---|---|---|
| Operating | ||
| Operating cash flow |
-0
|
-0
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Services-Management Consulting Services (SIC 8742)
- Listed as
- BDTB (OTC)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- Danville, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2041531
Other Services-Management Consulting Services companies
- Cgi Inc GIB
- Booz Allen Hamilton Holding Corp BAH
- Genpact LTD G
- Fti Consulting, Inc FCN
- Exponent Inc EXPO
- Huron Consulting Group Inc. HURN
- Astrana Health, Inc. ASTH
- ICF International, Inc. ICFI
Source: SEC EDGAR filings. This is company-reported data, not investment advice.